Fairmount Funds Management LLC — Form 4 insider transactions
Fairmount Funds Management LLC — Full 13F portfolio →
Buys and sells reported on SEC Form 4 — filed within two business days of each trade when a filer's ownership in a stock crosses 10%. This is the fastest public window into what the manager is doing.
| Transaction date | Activity | Security | Shares | Price | Total | Filing |
|---|---|---|---|---|---|---|
| 2026-09-03 | Disposition | Apogee Therapeutics, Inc. | 51,166 | — | — | SEC filing |
| 2026-09-03 | Disposition | Apogee Therapeutics, Inc. | 340,855 | — | — | SEC filing |
| 2026-08-07 | Opt exercise | Apogee Therapeutics, Inc. | 10,370 | $43.85 | $454,724 | SEC filing |
| 2026-08-07 | Opt exercise | Apogee Therapeutics, Inc. | 31,838 | $17.00 | $541,246 | SEC filing |
| 2026-07-16 | Buy | CRESCENT BIOPHARMA, INC. | 853,450 | $14.50 | $12,375,025 | SEC filing |
| 2026-07-01 | Sell | Oruka Therapeutics, Inc. | 3,553,410 | $84.43 | $300,014,406 | SEC filing |
| 2026-07-01 | Conversion | Oruka Therapeutics, Inc. | 3,553,410 | — | — | SEC filing |
| 2026-06-23 | Sell | Spyre Therapeutics, Inc. | 4,684,781 | $85.31 | $399,658,667 | SEC filing |
| 2026-06-23 | Conversion | Spyre Therapeutics, Inc. | 666,680 | — | — | SEC filing |
| 2026-05-11 | Buy | Viridian Therapeutics, Inc.\DE | 1,176,470 | $17.00 | $19,999,990 | SEC filing |
How Form 4 differs from 13F
13F filings are quarterly snapshots, up to 45 days late. Form 4 is transaction-level and lands within two business days — but only covers stocks where the filer reports beneficial ownership above 10%. Pair the two: 13F for the whole portfolio, Form 4 for what the largest holders are doing right now.